Related Experiment Video
Updated: Apr 26, 2026
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Cyr61 silencing reduces vascularization and dissemination of osteosarcoma tumors
11] Inserm U981, Institut de cancérologie Gustave Roussy, Villejuif, France [2] Gustave Roussy, Villejuif, France [3] Université Paris Sud, Orsay, France [4] Université Paris Diderot, Paris, France.
Abstract:
Osteosarcoma is the most prevalent primary pediatric cancer-related bone disease. These tumors frequently develop resistance to chemotherapy and are highly metastatic, leading to poor outcome. Thus, there is a need for new therapeutic strategies that can prevent cell dissemination. We previously showed that CYR61/CCN1 expression in osteosarcoma cells is correlated to aggressiveness both in vitro and in vivo in mouse models, as well as in patients. In this study, we found that CYR61 is a critical contributor to the vascularization of primary tumor. We demonstrate that silencing CYR61, using lentiviral transduction, leads to a significant reduction in expression level of pro-angiogenic markers such as VEGF, FGF2, PECAM and angiopoietins concomitantly to an increased expression of major anti-angiogenic markers such as thrombospondin-1 and SPARC. Matrix metalloproteinase-2 family member expression, a key pathway in osteosarcoma metastatic capacity was also downregulated when CYR61 was downregulated in osteosarcoma cells. Using a metastatic murine model, we show that CYR61 silencing in osteosarcoma cells results in reduced tumor vasculature and slows tumor growth compared with control. We also find that microvessel density correlates with lung metastasis occurrence and that CYR61 silencing in osteosarcoma cells limits the number of metastases. Taken together, our data indicate that CYR61 silencing can blunt the malignant behavior of osteosarcoma tumor cells by limiting primary tumor growth and dissemination process.
Insights
Targeting CYR61 (CCN1) in osteosarcoma cells significantly reduces tumor growth and metastasis. Silencing this protein inhibits pro-angiogenic factors, decreasing vascularization and limiting cancer spread in pediatric bone disease models.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Osteosarcoma is a primary bone cancer in children with poor outcomes due to chemotherapy resistance and high metastatic potential.
- CYR61/CCN1 expression correlates with osteosarcoma aggressiveness and is a potential therapeutic target.
- Novel strategies are needed to inhibit cancer cell dissemination and improve treatment efficacy.
Purpose of the Study:
- To investigate the role of CYR61 in osteosarcoma vascularization and metastasis.
- To evaluate the therapeutic potential of silencing CYR61 in osteosarcoma.
- To determine the impact of CYR61 on tumor growth, angiogenesis, and metastatic spread.
Main Methods:
- Silencing CYR61 expression in osteosarcoma cells using lentiviral transduction.
- Analyzing the expression of pro- and anti-angiogenic markers (VEGF, FGF2, PECAM, angiopoietins, thrombospondin-1, SPARC).
- Evaluating the effect of CYR61 silencing on tumor growth, vascularization, and lung metastasis in a murine model.
Main Results:
- CYR61 silencing significantly reduced pro-angiogenic markers and increased anti-angiogenic markers.
- Downregulation of CYR61 led to decreased expression of matrix metalloproteinase-2 family members, impacting metastatic capacity.
- Silencing CYR61 in osteosarcoma cells reduced tumor vasculature, slowed tumor growth, and limited lung metastasis in vivo.
- Reduced microvessel density correlated with decreased lung metastasis occurrence.
Conclusions:
- CYR61 is a critical factor in osteosarcoma vascularization and metastasis.
- Silencing CYR61 effectively blunts osteosarcoma's malignant behavior by inhibiting primary tumor growth and dissemination.
- Targeting CYR61 represents a promising therapeutic strategy for osteosarcoma, potentially improving patient outcomes.
More Related Videos
11:15A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
04:25Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
